Evidence map›Paper›PMID 26527895›Full record

ReviewInternational journal of general medicine2015

Managing neurocysticercosis: challenges and solutions.

Yannick Fogoum Fogang, Abdoul Aziz Savadogo, Massaman Camara, Dènahin Hinnoutondji Toffa, Anna Basse, Adjaratou Djeynabou Sow, Mouhamadou Mansour Ndiaye

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of general medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06376396 (Assessment of Combined Antiparasitic Drugs Praziquantel and Albendazole Versus Albendazole Alone in the Treatment of Active Parenchymal Neurocysticercosis in Tanzania and Zambia), which is not on this map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06376396 phase4not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Assessment of Combined Antiparasitic Drugs Praziquantel and Albendazole Versus Albendazole Alone in the Treatment of Active Parenchymal Neurocysticercosis in Tanzania and Zambia

TypeinterventionalSponsorR-Evolution Worldwide S.r.l. Impresa SocialeRan2024 to 2026Enrolled300ConditionsNeurocysticercosisArmsalbendazole and praziquantel, Albendazole
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Observational
  20. Use of Ivermectin in Neurocysticercosis: A Case Report.The American journal of case reports · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yannick Fogoum FogangNeurology Department, Fann Teaching Hospital, Cheikh Anta Diop University, Dakar, Senegal.
Abdoul Aziz SavadogoNeurology Department, Fann Teaching Hospital, Cheikh Anta Diop University, Dakar, Senegal.
Massaman CamaraNeurology Department, Fann Teaching Hospital, Cheikh Anta Diop University, Dakar, Senegal.
Dènahin Hinnoutondji ToffaNeurology Department, Fann Teaching Hospital, Cheikh Anta Diop University, Dakar, Senegal.
Anna BasseNeurology Department, Fann Teaching Hospital, Cheikh Anta Diop University, Dakar, Senegal.
Adjaratou Djeynabou SowNeurology Department, Fann Teaching Hospital, Cheikh Anta Diop University, Dakar, Senegal.
Mouhamadou Mansour NdiayeNeurology Department, Fann Teaching Hospital, Cheikh Anta Diop University, Dakar, Senegal.
Cheikh Anta Diop University · SN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Taenia solium neurocysticercosis (NCC) is a major cause of neurological morbidity in the world. Variability in the neuropathology and clinical presentation of NCC often make it difficult to diagnose and manage. Diagnosis of NCC can be challenging especially in endemic and resource-limited countries where laboratory and imaging techniques are often lacking. NCC management can also be challenging as current treatment options are limited and involve symptomatic agents, antiparasitic agents, or surgery. Although antiparasitic treatment probably reduces the number of active lesions and long-term seizure frequency, its efficacy is limited and strategies to improve treatment regimens are warranted. Treatment decisions should be individualized in relation to the type of NCC. Initial measures should focus on symptomatic management, with antiparasitic therapy only to be considered later on, when appropriate. Symptomatic treatment remains the cornerstone in NCC management which should not only focuses on epilepsy, but also on other manifestations that cause considerable burden (recurrent headaches, cognitive decline). Accurate patients' categorization, better antiparasitic regimens, and definition of new clinical outcomes for trials on NCC could improve management quality and prognosis of NCC. Prevention strategies targeting tapeworm carriers and infected pigs are yielding good results in local models. If local elimination of transmission is confirmed and replicated, this will open the door to cysticercosis eradication efforts worldwide.

Indexed as

albendazoleepilepsyheadacheneurocysticercosispraziquantelTaenia solium

Identifiers

PMID26527895
PMCPMC4621219
OpenAlexW2109800505

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.